These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 23815950)

  • 21. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.
    Coppola A; Tagliaferri A; Di Capua M; Franchini M
    Semin Thromb Hemost; 2012 Feb; 38(1):79-94. PubMed ID: 22314606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
    Boban A; Hermans C
    Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
    [No Abstract]   [Full Text] [Related]  

  • 24. Hemophilia A--from basic science to clinical practice.
    Klinge J; Ananyeva NM; Hauser CA; Saenko EL
    Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
    Franchini M; Coppola A; Rocino A; Santagostino E; Tagliaferri A; Zanon E; Morfini M;
    Semin Thromb Hemost; 2013 Oct; 39(7):752-66. PubMed ID: 24022806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options.
    Shetty S; Bhave M; Ghosh K
    Autoimmun Rev; 2011 Apr; 10(6):311-6. PubMed ID: 21115138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Factor V and Factor VIII Deficiency.
    Spreafico M; Peyvandi F
    Semin Thromb Hemost; 2009 Jun; 35(4):390-9. PubMed ID: 19598067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coagulation factors with improved properties for hemophilia gene therapy.
    Pipe SW
    Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in hemophilia.
    Tann G
    Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):218-28. PubMed ID: 524146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment strategies in children with hemophilia.
    Petrini P
    Paediatr Drugs; 2002; 4(7):427-37. PubMed ID: 12083971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central venous access devices in patients with hemophilia.
    Valentino LA; Kapoor M
    Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors that influence the bleeding phenotype in severe hemophilic patients.
    Rendo P; Shafer F; Korth-Bradley JM; Sivamurthy K; Korin J
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):683-90. PubMed ID: 24056291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnosis and management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2020; 61(9):1338-1348. PubMed ID: 33162534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
    Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.